Over-the-counter minoxidil foam and liquid solutions remain the gold standard for treating pattern hair loss across the United States, yet roughly 60 percent of users never see meaningful regrowth after months of twice-daily application. The failure rarely stems from product strength or inconsistent bathroom routines. Instead, trichology research points to a biochemical bottleneck inside the hair follicle itself: without adequate levels of a specific scalp enzyme known as sulfotransferase (SULT1A1), topical minoxidil remains biologically inert. For the millions of consumers who naturally lack sufficient enzymatic activity in their scalp tissue, standard hair loss foams simply sit on the skin unable to trigger new growth unless paired with catalytic adjuncts like topical tretinoin or mechanical microneedling.

Understanding this enzymatic mechanism has reshaped how cosmetic chemists, compounding pharmacies, and dermatologists approach androgenetic alopecia, a condition that affects approximately 50 percent of the population by age 50.

Rather than abandoning minoxidil or endlessly increasing concentration percentages, modern hair restoration protocols focus on waking up the follicle's dormant metabolic machinery.

The Prodrug Problem: Why SULT1A1 Dictates Regrowth

In its bottled foam or liquid form, minoxidil is a prodrug—a pharmacologically inactive compound that must undergo a chemical conversion inside the body before it can function. When applied to the scalp, the raw minoxidil molecule travels down into the hair follicle, where it relies on sulfotransferase enzymes (principally SULT1A1) located in the outer root sheath to add a sulfate molecule. This reaction converts the formula into minoxidil sulfate, the active metabolite that opens cellular potassium channels, widens local blood vessels, and extends the follicle's anagen growth phase.

The consumer catch is that SULT1A1 expression varies dramatically from person to person due to genetic polymorphisms.

Clinical trials cited by Dermatologic Therapy demonstrate that only 30 to 40 percent of patients using 2 percent or 5 percent topical minoxidil monotherapy achieve significant cosmetic regrowth. In one 16-week monotherapy study of 5 percent topical minoxidil, just 38.6 percent of participants experienced visible hair growth.

Diagnostic evaluations of plucked hair follicles confirm this divide. An enzymatic assay study published in Dermatologic Therapy found that measuring baseline SULT1A1 activity predicted a patient's response to minoxidil with 95 percent sensitivity and 73 percent specificity. Similarly, a prospective observational study of 60 male patients conducted at Ain Shams University Hospital and published in QJM: An International Journal of Medicine verified that sulfotransferase assay testing reliably separates responders from non-responders prior to starting a multi-month regimen.

How Tretinoin Primes the Follicular Pump

For decades, dermatologists observed that pairing minoxidil with topical tretinoin (all-trans retinoic acid, a prescription vitamin A derivative commonly used for acne and photoaging) improved hair density in stubborn cases.

Early theories assumed the retinoid simply exfoliated the stratum corneum, thinning the outer layer of scalp skin so more liquid could seep through. Pharmacokinetic reviews published in PubMed Central note that applying tretinoin cream prior to minoxidil increases systemic drug absorption nearly threefold due to enhanced skin permeability.

However, biochemical investigations revealed a deeper cellular interaction. Rather than acting merely as a surface peel, tretinoin directly upregulates the expression of sulfotransferase enzymes inside the follicle. In a pivotal clinical study documented in PubMed, researchers tested 20 men and women with androgenetic alopecia who applied 0.1 percent topical tretinoin cream to their scalps for five consecutive days. Among the participants initially classified by enzymatic testing as minoxidil non-responders, five days of tretinoin application raised mean follicular enzyme activity from 0.26 to 0.35 (p=0.0397), converting 43 percent of those non-responders into predicted responders.

This finding fueled a surge in customized 503A pharmacy compounding across the tele-dermatology sector, where prescription hair drops routinely blend 5 percent minoxidil with low-dose tretinoin.

Still, clinicians advise caution: combining retinoids with alcohol-based minoxidil vehicles frequently triggers scalp irritation, flaking, and contact dermatitis, requiring careful moisturizing protocols or foam-based alternatives.

Microneedling as a Mechanical Catalyst

For consumers looking to avoid prescription retinoids, mechanical scalp stimulation offers an alternative pathway to enzyme activation. Cosmetic microneedling—using a specialized dermaroller or motorized stamping pen fitted with fine needles to create microscopic channels in the scalp—has long been utilized to physically push topical serums past the skin barrier.

Beyond physical penetration, the controlled micro-injury initiates a localized wound-healing cascade that alters follicular biochemistry. When needles puncture the dermis, the tissue releases platelet-derived growth factors, vascular endothelial growth factor (VEGF), and Wnt/β-catenin signaling proteins. Crucially, this healing response also stimulates SULT1A1 production.

According to multi-center research published in the Journal of Biological Regulators and Homeostatic Agents (indexed via PubMed), performing once-weekly scalp microneedling over a 21-day period produced a median increase in follicular sulfotransferase activity of 37.5 percent.

Earlier 12-week clinical trials pairing microneedling with topical minoxidil demonstrated up to a fourfold increase in treatment efficacy and a 40 percent boost in hair count compared to minoxidil alone. Trichologists emphasize that spacing sessions appropriately is vital, as overly aggressive or daily needling can induce chronic inflammation and follicular scarring.

Does Oral Minoxidil Bypass the Scalp Enzyme Entirely?

As awareness of SULT1A1 deficiency has grown, many dermatologists have shifted patients toward low-dose oral minoxidil, an off-label pill prescription typically dosed between 1 mg and 5 mg daily. The prevailing clinical rationale is that ingested minoxidil absorbs into the bloodstream and passes through the liver, where abundant hepatic sulfotransferase enzymes efficiently convert the drug into active minoxidil sulfate before circulating it back to the scalp.

Recent clinical data suggest the comparison between oral and topical routes is nuanced.

In a double-blind, placebo-controlled randomized clinical trial of 90 men conducted at São Paulo State University and published in JAMA Dermatology, taking 5 mg of oral minoxidil once daily for 24 weeks showed comparable overall efficacy to applying 5 percent topical minoxidil twice daily, though the oral tablet demonstrated superior vertex improvement. Meanwhile, a separate study indexed in PubMed evaluating oral minoxidil in androgenetic alopecia patients found that individuals with low follicular SULT1A1 activity still achieved favorable hair growth with the oral tablet, while also noting that local follicle enzyme dynamics remain relevant to personalized therapy.

What Consumers Should Know Before Changing Routines

How long does it take to know if you are a minoxidil non-responder?

Clinical guidelines indicate that visible hair density changes require at least three to six months of consistent daily application. Users who see zero reduction in shedding or no vellus hair sprouting after six months of proper scalp contact are frequently dealing with low SULT1A1 enzyme activity.

Will switching from 5% foam to 10% or 15% liquid fix an enzyme deficiency?

For true enzymatic non-responders, simply applying a higher percentage of minoxidil rarely solves the issue. While higher concentrations can help a subset of borderline users, if the hair follicle lacks the SULT1A1 catalyst to sulfonate the molecule, excess raw minoxidil remains dormant on the scalp.

Can you apply tretinoin and minoxidil at the same time?

Yes, though many dermatologists recommend applying a pea-sized amount of tretinoin or using a pre-compounded evening solution once daily rather than twice daily to minimize scalp peeling and redness, while keeping microneedling sessions strictly limited to once a week or once every two weeks.

Sources

  • PubMed Central - Efficacy of Topical Tretinoin and Topical Minoxidil Cotherapy in Androgenetic Alopecia: A Review
  • PubMed - Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes
  • Dermatologic Therapy (Ovid) - Novel enzymatic assay predicts minoxidil response in androgenetic alopecia
  • PubMed - Microneedling improves minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes
  • QJM: An International Journal of Medicine - Value of Sulfotransferase Enzyme Assay in Predicting Minoxidil Response in Patients with Androgenetic Alopecia
  • JAMA Dermatology (PubMed) - Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial
  • PubMed - Hair follicle sulfotransferase activity and effectiveness of oral minoxidil in androgenetic alopecia